<p>馬薩諸塞州劍橋 --（商業資訊）--Scholar Rock（納斯達克代碼：SRRK；以下簡稱 “公司”）今天宣佈，公司向兩名新聘員工授予了總計 7,800 股普通股的誘導性股權獎勵，其中包括總計 4,457 股普通股的誘導性股票期權和總計 3,343 股普通股的誘導性限制性股票單位。</p>
<p>這些獎勵受公司 2022 年誘導性股權計劃（以下簡稱 “計劃”）中規定的所有條款、條件和其他條款的約束。</p>
<p>該計劃最初由公司董事會於 2022 年 6 月 16 日通過，並不時修訂，專門用於向未曾是 Scholar Rock 員工的個人授予股權獎勵，或在經過真實的非就業期後，作為誘導這些個人與 Scholar Rock 簽訂僱傭合同的重要條件，符合納斯達克上市規則 5635(c)(4)。</p>
<p>誘導性股票期權的行使價格為 45.25 美元，等於 Scholar Rock 普通股在 2025 年 12 月 8 日的收盤價。誘導性股票期權將在每位員工入職一週年時，歸屬與獎勵相關的 25% 普通股，剩餘的 75% 普通股將在此後以 12 個相等的季度分期歸屬。誘導性限制性股票單位的歸屬將分為四個相等的年度分期。所有與誘導性獎勵相關的歸屬均需員工在適用的歸屬日期繼續在公司服務。</p>
<p><strong>關於 Scholar Rock</strong></p>
<p>Scholar Rock 是一家處於後期階段的生物製藥公司，專注於為患有脊髓性肌萎縮症（SMA）及其他罕見、嚴重和致殘的神經肌肉疾病的兒童和成人開發和商業化 apitegromab。作為肌肉生物學領域的全球領導者，該領域專注於調節肌肉質量的蛋白質，生物製藥公司以學者岩石與蛋白質結構的視覺相似性命名。我們致力於解鎖根本不同的治療方法，依靠廣泛應用的專有平台，該平台開發了新型單克隆抗體，以極高的選擇性調節蛋白質生長因子。Scholar Rock 每天努力通過其高度創新的抗肌肉抑制素項目為患者創造新的可能性，包括在其他罕見神經肌肉疾病中的機會。瞭解更多信息，請訪問 ScholarRock.com，並在 X 和 LinkedIn 上關注 @ScholarRock。</p>
<p>Scholar Rock®是 Scholar Rock, Inc.的註冊商標。</p>
<p><strong>關於 Scholar Rock 的其他信息的可用性</strong></p>
<p>投資者和其他人應注意，我們通過公司網站 www.scholarrock.com 與投資者和公眾溝通，包括但不限於公司披露、投資者演示文稿和常見問題解答、證券交易委員會的備案、新聞稿、公開電話會議記錄和網絡廣播記錄，以及在 X（前稱 Twitter）和 LinkedIn 上的信息。我們在網站或 X（前稱 Twitter）或 LinkedIn 上發佈的信息可能被視為重要信息。因此，我們鼓勵投資者、媒體和其他感興趣的人定期查看我們發佈的信息。我們網站或社交媒體的內容不應被視為納入 1933 年證券法（經修訂）下的任何備案。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI2MDE0MDFyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI2MDE0MDFyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251212601401/en/</p>
<p><strong>Scholar Rock</strong></p>
<p><strong>投資者</strong></p>
<p>Laura Ekas, Ph.D.</p>
<p><strong>ir@scholarrock.com</strong></p>
<p>917-439-0374</p>
<p><strong>媒體</strong></p>
<p>Molly MacLeod</p>
<p><strong>media@scholarrock.com</strong></p>
<p>802-579-5995</p>
<p>來源：Scholar Rock</p>

SRRK

<p>Scholar Rock 宣佈根據納斯達克上市規則 5635(c)(4) 為兩名新員工授予誘導性股權獎勵，總計 7,800 股普通股。這些獎勵包括股票期權和限制性股票單位，受公司 2022 年誘導性股權計劃的約束。Scholar Rock 是一家專注於開發神經肌肉疾病治療方案的生物製藥公司</p>

<p>CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), today announced that the company granted inducement equity awards covering an aggregate of 7,800 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 4,457 shares of common stock and inducement restricted stock units, covering an aggregate of 3,343 shares of its common stock.</p>
<div class="lb-trans"><p>馬薩諸塞州劍橋 --（商業資訊）--Scholar Rock（納斯達克代碼：SRRK；以下簡稱 “公司”）今天宣佈，公司向兩名新聘員工授予了總計 7,800 股普通股的誘導性股權獎勵，其中包括總計 4,457 股普通股的誘導性股票期權和總計 3,343 股普通股的誘導性限制性股票單位。</p>
</div><p>The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (the “Plan”) and the award agreements thereunder.</p>
<div class="lb-trans"><p>這些獎勵受公司 2022 年誘導性股權計劃（以下簡稱 “計劃”）中規定的所有條款、條件和其他條款的約束。</p>
</div><p>The Plan, initially adopted by the Company’s board of directors on June 16, 2022, and as amended from time to time, is used exclusively for the grant of equity awards to individuals who were not previously employees of Scholar Rock, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Scholar Rock, pursuant to Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>該計劃最初由公司董事會於 2022 年 6 月 16 日通過，並不時修訂，專門用於向未曾是 Scholar Rock 員工的個人授予股權獎勵，或在經過真實的非就業期後，作為誘導這些個人與 Scholar Rock 簽訂僱傭合同的重要條件，符合納斯達克上市規則 5635(c)(4)。</p>
</div><p>The inducement stock options have an exercise price of $45.25, which is equal to the closing price of Scholar Rock’s common stock on December 8, 2025. The inducement stock options will vest with respect to 25% of the shares of common stock underlying the award on the first anniversary of each employee’s start date, and the remaining 75% of the shares of common stock underlying the inducement stock options will vest in 12 equal quarterly installments thereafter. Vesting for the inducement restricted stock units will be in four equal annual installments. All vesting related to inducement awards is subject to the employees’ continuing service at the Company through the applicable vesting date.</p>
<div class="lb-trans"><p>誘導性股票期權的行使價格為 45.25 美元，等於 Scholar Rock 普通股在 2025 年 12 月 8 日的收盤價。誘導性股票期權將在每位員工入職一週年時，歸屬與獎勵相關的 25% 普通股，剩餘的 75% 普通股將在此後以 12 個相等的季度分期歸屬。誘導性限制性股票單位的歸屬將分為四個相等的年度分期。所有與誘導性獎勵相關的歸屬均需員工在適用的歸屬日期繼續在公司服務。</p>
</div><p><strong>About Scholar Rock</strong></p>
<div class="lb-trans"><p><strong>關於 Scholar Rock</strong></p>
</div><p>Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.</p>
<div class="lb-trans"><p>Scholar Rock 是一家處於後期階段的生物製藥公司，專注於為患有脊髓性肌萎縮症（SMA）及其他罕見、嚴重和致殘的神經肌肉疾病的兒童和成人開發和商業化 apitegromab。作為肌肉生物學領域的全球領導者，該領域專注於調節肌肉質量的蛋白質，生物製藥公司以學者岩石與蛋白質結構的視覺相似性命名。我們致力於解鎖根本不同的治療方法，依靠廣泛應用的專有平台，該平台開發了新型單克隆抗體，以極高的選擇性調節蛋白質生長因子。Scholar Rock 每天努力通過其高度創新的抗肌肉抑制素項目為患者創造新的可能性，包括在其他罕見神經肌肉疾病中的機會。瞭解更多信息，請訪問 ScholarRock.com，並在 X 和 LinkedIn 上關注 @ScholarRock。</p>
</div><p>Scholar Rock® is a registered trademark of Scholar Rock, Inc.</p>
<div class="lb-trans"><p>Scholar Rock®是 Scholar Rock, Inc.的註冊商標。</p>
</div><p><strong>Availability of Other Information About Scholar Rock</strong></p>
<div class="lb-trans"><p><strong>關於 Scholar Rock 的其他信息的可用性</strong></p>
</div><p>Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website or on X (formerly known as Twitter) or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.</p>
<div class="lb-trans"><p>投資者和其他人應注意，我們通過公司網站 www.scholarrock.com 與投資者和公眾溝通，包括但不限於公司披露、投資者演示文稿和常見問題解答、證券交易委員會的備案、新聞稿、公開電話會議記錄和網絡廣播記錄，以及在 X（前稱 Twitter）和 LinkedIn 上的信息。我們在網站或 X（前稱 Twitter）或 LinkedIn 上發佈的信息可能被視為重要信息。因此，我們鼓勵投資者、媒體和其他感興趣的人定期查看我們發佈的信息。我們網站或社交媒體的內容不應被視為納入 1933 年證券法（經修訂）下的任何備案。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI2MDE0MDFyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251212601401r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251212601401/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251212601401/en/</p>
</div><p><strong>Scholar Rock</strong></p>
<div class="lb-trans"><p><strong>Scholar Rock</strong></p>
</div><p><strong>Investors</strong></p>
<div class="lb-trans"><p><strong>投資者</strong></p>
</div><p>Laura Ekas, Ph.D.</p>
<div class="lb-trans"><p>Laura Ekas, Ph.D.</p>
</div><p><strong>ir@scholarrock.com</strong></p>
<div class="lb-trans"><p><strong>ir@scholarrock.com</strong></p>
</div><p>917-439-0374</p>
<div class="lb-trans"><p>917-439-0374</p>
</div><p><strong>Media</strong></p>
<div class="lb-trans"><p><strong>媒體</strong></p>
</div><p>Molly MacLeod</p>
<div class="lb-trans"><p>Molly MacLeod</p>
</div><p><strong>media@scholarrock.com</strong></p>
<div class="lb-trans"><p><strong>media@scholarrock.com</strong></p>
</div><p>802-579-5995</p>
<div class="lb-trans"><p>802-579-5995</p>
</div><p>Source: Scholar Rock</p>
<div class="lb-trans"><p>來源：Scholar Rock</p>
</div>

Scholar Rock 根據納斯達克上市規則 5635(c)(4) 報告新的員工激勵授予 | SRRK 股票新聞